ARTICLES BY LOUIS

• From JP Morgan: CDMOs Have A Change Of Heart

  1/29/2025

  CDMOs seem determined to do two things more strategically and with a greater focus: build on what they do best (instead of spreading across services); and differentiate themselves by a devotion to customer service. Part two from JPM25.

• An Outsourcing Vibe At JP Morgan 25

  1/28/2025

  The JP Morgan Healthcare conference has never been a venue for directed discussion on outsourcing. That’s not to say such discussions aren’t held. This year, Kurt Nielsen co-hosted an evening devoted to the topic. Nielsen, a veteran outsourcing-industry executive, shares his initial thoughts on the vibe this year.

• How Biotech Academy In Rome Is Reshaping Workforce Readiness

  1/27/2025

  As the biotech industry continues to evolve, a growing gap in workforce readiness has emerged, driven by insufficient training for both new graduates and experienced professionals transitioning to advanced bioprocessing. Biotech Academy in Rome's Leonardo Sibilio addresses this challenge.

• The Intelligent CDMO: A Vision With Agentic AI

  1/20/2025

  Agentic AI is the next artificial-intelligence iteration for the biopharma industry. It propels prediction to autonomous decision-making. It can usher in transformative efficiencies to CDMOs. If you've day-dreamed of more effective external-support, this may be a ticket to that destination.

• Autonomous Decision-Making: Are We Ready For Agentic AI

  1/15/2025

  The biopharma industry has generative artificial intelligence (AI) in its employ. After a long wait, we’ve adopted it rather suddenly. Just in time for a new kid in town. Next to ride in is Agentic AI. It will more robustly revolutionize our drug development and manufacturing. A preview of what's to come.

• It's Partly Personal (Medicine): In 10 Years Outsourcing At $315 Billion

  1/13/2025

  You’ve got to give Towards Healthcare credit. They've the fortitude to publish a 10-year projection of how much development and manufacturing outsourcing will add up to globally. Interestingly, personalized medicine may play an outsized role in that growth. Chief Editor Louis Garguilo takes a deeper dive into the Pharmaceutical CDMO Market Companies, Advantages and Segmental Analysis.

• 2024 Made Us Nervous. Will 2025 Be A Happier New Year?

  1/6/2025

  Chief Editor Louis Garguilo doesn't recall a time of more collective concern over development and manufacturing outsourcing than exhibited during last year's news of Novo Holdings’ purchase of Catalent, and the sale of certain Catalent facilities to Novo Nordisk. That angst was aggravated by the simultaneous drama known as the BIOSECURE Act. Will we have a calmer 2025?

• 2025: Navigating Partnerships Amid Political And Economic Shifts

  1/2/2025

  Brace for a potentially turbulent 2025. That’s the collective message members of the Outsourced Pharma Editorial Advisory Board provided Chief Editor Louis Garguilo for his first editorial of 2025. They reveal a landscape where geopolitical tensions, regulatory evolutions, and emerging technologies will affect how you develop and manufacture drugs.

• 2024 Review: It Was Your Moment In Outsourcing History

  12/17/2024

  Chief Editor Louis Garguilo writes that 2024 sent us a harsh reminder: None of us are paragons of outsourcing sagacity. We need to keep learning, and updating. And staying aware that the outside world – history in the making– interferes. Here's a review of a historic year that will get you thinking: How did I create outsourcing history in 2024?

• Biotechs Should Go With An Uber Not A Limo

  12/12/2024

  Bob Discordia had been in stealth mode for a while. When he finally emerged, Chief Editor Louis Garguilo knew his newco would include a precise model of outsourcing. The reveal came earlier this year with the announcement he had founded EQUULUS Therapeutics, a neuroscience biotech. So how will Discordia outsource? He'll take an Uber ... and advises you do the same.